CytoSorbents Corporation Broadens its Intellectual Property Portfolio
Complete the form below to unlock access to ALL audio articles.
CytoSorbents Corporation, a critical care focused company using blood purification to treat life-threatening illnesses, announced the issuance of two additional U.S. patents, bringing its total patent portfolio to 29 issued patents.
U.S. Patent 7,846,650 is titled "Methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood" and covers a number of different hemocompatible device configurations to treat a variety of acute and chronic disorders including sepsis, trauma, myocardial ischemia and reperfusion injury, biologic or chemical warfare, renal disease, and others.
U.S. Patent 7,875,182 titled "Size-selective hemoperfusion polymeric adsorbents" describes the production of polymer beads ideally suited for the treatment of chronic diseases such as renal failure and auto-immune diseases.
Dr. Phillip Chan, Chief Executive Officer, stated, "These awarded patents add to an already substantial patent portfolio that broadly covers the use of our biocompatible porous polymer beads to treat a variety of conditions and diseases. We continue to invest significantly in research and development, expanding the potential applications of our purification technology, and increasing our pipeline of licensable products. Our long-term goal is to maximize the value of our technology and create lasting shareholder value."